Related Experiment Videos
Genitourinary rhabdomyosarcoma in children
K R Loughlin1, A B Retik, H J Weinstein
1Department of Surgery, Children's Hospital, Boston, MA 02115.
Insights
Genitourinary rhabdomyosarcoma in children is rare but challenging. Paratesticular tumors show the best survival rates, while bladder/prostate tumors require innovative treatments beyond current standards.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Genitourinary rhabdomyosarcoma is an uncommon pediatric malignancy.
- This tumor presents significant therapeutic challenges for multidisciplinary teams.
Purpose of the Study:
- To review treatment outcomes for children with genitourinary rhabdomyosarcoma.
- To identify prognostic factors and evaluate treatment strategies.
Main Methods:
- Retrospective analysis of 36 children treated between 1957 and 1985.
- Treatment modalities included surgery, chemotherapy, and radiation therapy.
Main Results:
- Overall event-free survival was 74%.
- Paratesticular tumors had the best prognosis (88% event-free survival), with negative retroperitoneal lymph nodes obviating regional radiation.
- Bladder/prostate tumors had lower survival and functional outcomes, with conservative surgery often compromising bladder integrity.
Conclusions:
- Paratesticular rhabdomyosarcoma has a favorable prognosis with appropriate management.
- Current multimodal therapy is insufficient for bladder/prostate rhabdomyosarcoma, necessitating novel therapeutic approaches.
Abstract:
Although rhabdomyosarcoma of the genitourinary tract occurs infrequently in children, it presents a challenging problem to the surgeon, radiotherapist, and oncologist. Thirty-six children with genitourinary rhabdomyosarcoma were treated at our institutions from 1957 to 1985. The primary site of tumor involved the bladder, prostate, or both in 15 patients, the paratesticular structures in 12, and female reproductive organs in nine. Although treatment modalities and philosophies of care varied over the past 27 years, the majority of patients were treated with a combination of surgery, chemotherapy, and radiation therapy. The event-free survival for all patients is 74%. Patients with paratesticular tumors had the best prognosis (88% event-free survival). Regional nodal radiation therapy is not necessary in this favorable group if the retroperitoneal lymph node dissection is negative. Of 15 children with bladder/prostate tumors nine had initial conservative surgery. Of these nine six are long-term survivors, but only three patients have intact bladders. The girls with tumors of the reproductive organs had an event-free survival of 63%; all patients in this group had hysterectomies. Chemotherapy and radiotherapy have not substituted for radical surgical procedures in most children with bladder or prostate rhabdomyosarcomas. Innovative therapeutic approaches are necessary for this group of patients.